Characterisation of tumour-infiltrating macrophages: Impact on response and survival in patients receiving primary chemotherapy for breast cancer

Breast Cancer Research and Treatment

Volumn 135, Issue 2, 2012, Pages 539-548

  Heys, Steven D ^a   Stewart, Keith N ^a   McKenzie, Emma J ^a   Miller, Iain D ^b   Wong, Simon Y C ^a   Sellar, Grant ^c,d   Rees, Andrew J ^e  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^d HERIOT WATT UNIVERSITY   (United Kingdom)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Breast cancer; Chemotherapy; Tumour infiltrating macrophages

Indexed keywords

ANTHRACYCLINE; CD205 ANTIGEN; CD68 ANTIGEN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GLYCOPROTEIN P 15095; INTERLEUKIN 2 RECEPTOR ALPHA; LYMPHOCYTE ANTIGEN; PREDNISOLONE; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG RESPONSE; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; LYMPHOCYTE DIFFERENTIATION; MACROPHAGE FUNCTION; MACROPHAGE MIGRATION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT;

ADULT; AGED; ANTHRACYCLINES; ANTIGENS, CD; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CLINICAL TRIALS AS TOPIC; DENDRITIC CELLS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MACROPHAGES; MIDDLE AGED; MULTIVARIATE ANALYSIS; T-LYMPHOCYTES; TAXOIDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84866535934     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2190-6     Document Type: Article

References (51)

1. Heys SD (1991) Evolution of breast cancer management: focus on neoadjuvant chemotherapy. Breast Cancer 8:339-350
2. Kaufmann M, von Minckwitz G, Bear HD et al (2007) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 18:1927-1934 (Pubitemid 350286227)
3. Heys SD, Sarkar T, Hutcheon AW (2005) Primary docetaxel chemotherapy in patients with breast cancer: impact on response and survival. Breast Cancer Res Treat 90:169-185 (Pubitemid 40568900)
4. Smith IC, Heys SD, Hutcheon AW et al (2002) Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20:1456-1466 (Pubitemid 34260523)
5. Bear HD, Anderson S, Brown A et al (2003) The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21:4165-4174 (Pubitemid 46606185)
6. Bear HD, Anderson S, Smith RE et al (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24:2019-2027 (Pubitemid 46622110)
7. Rastogi P, Anderson SJ, Bear HD et al (2008) Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26:778-785 (Pubitemid 351264391)
8. Heys SD, Sarkar T, Hutcheon AW (2004) Docetaxel as adjuvant and neoadjuvant treatment for patients with breast cancer. Expert Opin Pharmacother 5:2147-2154
9. Colleoni M, Bagnardi V, Rotmensz N et al (2010) A nomogram based on the expression of Ki-67, steroid hormone receptors status and number of chemotherapy courses to predict pathological complete remission after preoperative chemotherapy for breast cancer. Eur J Cancer 46:2216-2224
10. Colleoni M, Viale G, Zahrieh D et al (2008) Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. Ann Oncol 19:465-472 (Pubitemid 351325666)
11. Miglietta L, Vanella P, Canobbio L et al (2009) Clinical and pathological response to primary chemotherapy in patients with locally advanced breast cancer grouped according to hormonal receptors, Her2 status, grading and Ki-67 proliferation index. Anticancer Res 29:1621-1625
12. Ring AE, Smith IE, Ashley S et al (2004) Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer 91:2012-2017 (Pubitemid 40128767)
13. Bonnefoi H, Potti A, Delorenzi M et al (2007) Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol 8:1071-1078 (Pubitemid 350182953)
14. Straver ME, Glas AM, Hannemann J et al (2010) The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 119:551-558
15. Sekine I, Shimizu C, Nishio K et al (2009) A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer. Int J Clin Oncol 14:112-119
16. Tewari M, Krishnamurthy A, Shukla HS (2008) Predictive markers of response to neoadjuvant chemotherapy in breast cancer. Surg Oncol 17:301-311
17. Martin-Richard M, Munoz M, Albanell J et al (2004) Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy. Oncology 66:388-394 (Pubitemid 39194361)
18. Schmitt M, Sweep FC (2009) Tissue inhibitor metalloproteinase type-1 (TIMP-1), a novel cancer biomarker predicting response of adjuvant anthracycline-based chemotherapy in patients afflicted with primary breast cancer. Eur J Cancer 45:2444-2446
19. Smith IC, Welch AE, Hutcheon AW et al (2000) Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 18:1676-1688 (Pubitemid 30220546)
20. Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, von Törne C, Weichert W, Engels K, Solbach C, Schrader I, Dietel M, von Minckwitz G (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28:105-113
21. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirström K, West BL, Coussens LM (2011) Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 1:54-67
22. + infiltrating cells in human breast cancer. Breast Cancer Res Treat 127:99-108
23. + regulatory T cells. Clin Cancer Res 14:2413-2420 (Pubitemid 351551075)
24. Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, Mènard S, Tagliabue E, Balsari A (2009) FOXP3 expression and overall survival in breast cancer. J Clin Oncol 27:1746-1752
25. de Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6:24-37 (Pubitemid 43053650)
26. Mantovani A, Allavena P, Sica A et al (2008) Cancer-related inflammation. Nature 454:436-444
27. Qualls JE, Murray PJ (2011) Tumor macrophages protective and pathogenic roles in cancer development. Curr Top Dev Biol 94:309-328
28. Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green AR (2012) Tumour-infiltrating macrophages and clinical outcome in breast cancer. J Clin Pathol 65(2):159-163
29. Tsutsui S, Yasuda K, Suzuki K et al (2005) Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep 14:425-431
30. Welm AL, Sneddon JB, Taylor C et al (2007) The macrophagestimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proc Natl Acad Sci USA 104:7570-7575 (Pubitemid 47185947)
31. Steidl C, Lee T, Shah SP et al (2010) Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 362:875-885
32. Nakano T, Oka K, Takahashi TM et al (1992) Roles of Langerhans' cells and T-lymphocytes infiltrating cancer tissues in patients treated by radiation therapy for cervical cancer. Cancer 70:2839-2844
33. Ashida A, Boku N, Aoyagi K et al (2006) Expression profiling of esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy: clinical implications. Int J Oncol 28:1345-1352
34. Taskinen M, Karjalainen-Lindsberg ML et al (2007) A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res 13:5784-5789 (Pubitemid 47591642)
35. Kawai O, Ishii G, Kubota K et al (2008) Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 113:1387-1395
36. Nelson BH (2008) The impact of T-cell immunity on ovarian cancer outcomes. Immunol Rev 222:101-116 (Pubitemid 351430376)
37. Ogston KN, Miller ID, Payne S et al (2003) A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 12:320-327 (Pubitemid 37322062)
38. Coghlin CL, Smith LJ, Bakar S et al (2010) Quantitative analysis of tumor in bronchial biopsy specimens. J Thorac Oncol 5:448-452
39. Murray GI, Patimalla S, Stewart KN et al (2010) Profiling the expression of cytochrome P450 in breast cancer. Histopathology 57:202-211
40. Leek RD, Lewis CE, Whitehouse R et al (1996) Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 56:4625-4629 (Pubitemid 26338061)
41. Zhang L, Conejo-Garcia JR, Katsaros D et al (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348:203-213 (Pubitemid 36077915)
42. Biswas SK, Mantovani A (2010) Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11:889-896
43. Wang YC, He F, Feng F et al (2010) Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses. Cancer Res 70:4840-4849
44. Kujawski M, Kortylewski M, Lee H et al (2008) Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Investig 118:3367-3377
45. Herrmann A, Kortylewski M, Kujawski M et al (2010) Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells. Cancer Res 70:7455-7464
46. Cho Y, Miyamoto M, Kato K, Fukunaga A, Shichinohe T, Kawarada Y et al (2003) CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res 63:1555-1559 (Pubitemid 36373643)
47. Movahedi K, Laoui D, Gysemans C et al (2010) Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6Chigh monocytes. Cancer Res 70:5728-5739
48. Dalpke A, Heeg K, Bartz H, Baetz A (2007) Regulation of innate immunity by suppressor of cytokine signaling (SOCS) proteins. Immunobiology 213:225-235
49. Liu Y, Stewart KN, Bishop E, Marek CJ, Kluth DC, Rees AJ, Wilson HM (2008) Unique expression of suppressor of cytokine signaling 3 is essential for classical macrophage activation in rodents in vitro and in vivo. J Immunol 180:6270-6278
50. Nakagawa R, Naka T, Tsutsui H et al (2002) SOCS-1 participates in negative regulation of LPS responses. Immunity 17:677-687 (Pubitemid 35351512)
51. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO, Green AR (2011) Tumor-infiltrating CD8? lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 29:1949-1955